Wearable AI to monitor heart function after lymphoma or sarcoma treatment
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
This project will test whether a smartwatch-based AI ECG combined with periodic echocardiograms can find early heart damage in lymphoma or sarcoma survivors treated with anthracycline chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT07058064 on ClinicalTrials.gov |
What this trial studies
This interventional program uses an Apple Watch with AI-enabled ECG monitoring alongside standard echocardiograms and LVEF measurements to provide long-term cardiovascular surveillance for cancer survivors. Participants are lymphoma or sarcoma patients who are starting anthracycline therapy or are within one year after completing it, and who do not have preexisting reduced LVEF or disqualifying arrhythmias. The study collects ECG data from a wearable, periodic echocardiographic imaging including LVEF, and biospecimens to correlate findings. The goal is a cost-effective, feasible approach to detect cardiotoxicity earlier and reduce progression to heart failure over extended follow-up.
Who should consider this trial
Good fit: Adults with lymphoma or sarcoma who are starting anthracycline treatment or are within one year after finishing it, have LVEF ≥50%, no prior heart failure or persistent arrhythmias, and can give informed consent and comply with study procedures.
Not a fit: Patients with baseline LVEF <50%, a prior history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm are excluded and unlikely to benefit from this surveillance strategy.
Why it matters
Potential benefit: If successful, this approach could enable earlier, low-cost detection of cardiotoxicity using wearable monitoring, helping prevent progression to heart failure and reduce related morbidity and mortality.
How similar studies have performed: Prior research has shown AI-enabled ECGs can detect reduced LVEF and that wearable ECG monitoring is feasible, but long-term outcome data specifically in cancer survivors remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Joerg Herrmann, MD — Mayo Clinic
- Study coordinator: Tera Peck
- Email: Peck.Tera@mayo.edu
- Phone: 507-266-2123
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.